Glaukos (NYSE:GKOS) Stock Gets Price Target Increase from BTIG Research

Glaukos (NYSE:GKOS – Get Free Report) had its price target raised by equities research analysts at BTIG Research from $234.00 to $252.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research‘s price objective would suggest a potential upside of 2.60% from the company’s current price.

GKOS has been the topic of several other reports. Truist Financial lifted their target price on Glaukos from $215.00 to $255.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Zacks Research raised Glaukos from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 28th. Citigroup raised their price objective on Glaukos from $225.00 to $247.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Piper Sandler reaffirmed an “overweight” rating and issued a $240.00 price objective (up from $195.00) on shares of Glaukos in a research note on Thursday, October 29th. Finally, JPMorgan Chase & Co. lifted their price objective on Glaukos from $200.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $218.00.

Check Out Our Latest Report on GKOS

Glaukos Trading Down 0.0%

Shares of NYSE GKOS opened at $245.60 on Monday. The firm has a 50 day moving average price of $184.61 and a two-hundred day moving average price of $147.10. The stock has a market cap of $14.54 billion, a P/E ratio of -83.54 and a beta of 0.68. Glaukos has a 52-week low of $87.32 and a 52-week high of $255.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57.

Glaukos (NYSE:GKOS – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. The company had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. Glaukos’s revenue was up 58.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.16) earnings per share. As a group, equities analysts forecast that Glaukos will post 0.50 EPS for the current year.

Insider Activity at Glaukos

In other news, Director Gilbert Kliman sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total transaction of $632,500.00. Following the completion of the sale, the director owned 37,406 shares of the company’s stock, valued at $9,463,718. This trade represents a 6.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 5.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantinno Capital Management LP raised its stake in Glaukos by 964.0% during the 1st quarter. Quantinno Capital Management LP now owns 30,836 shares of the medical instruments supplier’s stock worth $3,320,000 after buying an additional 27,938 shares during the period. TimesSquare Capital Management LLC bought a new position in Glaukos in the second quarter worth approximately $20,293,000. BlackRock Inc. bought a new stake in shares of Glaukos during the second quarter valued at approximately $1,333,318,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Glaukos during the second quarter valued at approximately $3,361,000. Finally, Wellington Management Group LLP raised its position in shares of Glaukos by 187.1% during the second quarter. Wellington Management Group LLP now owns 428,215 shares of the medical instruments supplier’s stock worth $59,847,000 after purchasing an additional 279,065 shares during the period. 99.04% of the stock is owned by institutional investors.

About Glaukos

(Get Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Read More

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.